NDAORALCAPSULE
Approved
Jun 2009
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
4
Data completeness
6/8 — Strong
ZIPSOR (diclofenac potassium) by Medica Corp is analgesic, anti-inflammatory, and antipyretic properties. Approved for post-operative pain, fever, sprains and strains. First approved in 2009.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIPSOR (diclofenac potassium) is an oral NSAID capsule approved in 2009 for acute pain management, including post-operative pain, sprains, strains, and fever. It works by inhibiting COX-1 and COX-2 enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain sensitization, and fever. The potassium salt formulation enables rapid absorption and onset of analgesia.
$0.797MPart D
LOE ApproachingDeclining
2.8 years to LOEMinimal market presence with low Part D claims suggests a small, contracting brand team focused on managed decline.
Mechanism of Action
analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of ZIPSOR, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac…
Indications (3)
Worked on ZIPSOR at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.